August 9, 2017

XOMA to Present New Growth Strategy at the 2017 Wedbush PacGrow Healthcare Conference

BERKELEY, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced that Jim Neal, Chief Executive Officer, will present the Company's new strategic initiatives and value drivers at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017, at 8:35 a.m. ET. The conference is being held at the Le Parker Meridien hotel in New York City.

A live audio webcast of the presentation can be accessed in the Investors section of XOMA's website at www.xoma.com. An archived version of the webcast will be available via replay for 90 days following the presentation.

About XOMA Corporation

XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company's pioneering efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. For more information, visit www.xoma.com.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: the potential of XOMA's portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time; the significant unmet therapeutic need for certain rare medical conditions associated with hyperinsulinism; XOMA's intent to license X213 and X358; and statements that otherwise relate to future periods. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

Investor contact:
Luke Heagle
Pure Communications, Inc.
+1 910-726-1372
lheagle@purecommunications.com

Media contact:
Colin Sanford
Pure Communications, Inc.
+1 415-946-1094
csanford@purecommunications.com

Source: XOMA Corporation